Serum AMH Levels in Women: Differences Between Endometrioma and Non-Endometrioma Cases

Background & Objective: The link between endometrioma and serum Anti-Müllerian Hormone (AMH) levels is crucial in predicting outcomes and informing clinical management strategies for affected individuals. Endometrioma may reduce ovarian reserve due to damage to ovarian tissue, which in turn affects AMH secretion. Clinically, AMH is a widely recognized marker for assessing ovarian reserve and is frequently utilized in diagnosing and forecasting infertility and reproductive conditions. This study was conducted with aim to investigate the differences in serum AMH levels between women with and without endometrioma. Materials & Methods: This cross-sectional analytical study was conducted on reproductive-aged women diagnosed with endometrioma at Hasan Sadikin Hospital, Bandung, from August 2022 to July 2024. The control group consisted of women without endometrioma, selected consecutively according to specific eligibility criteria, as AMH was not routinely measured in this population. A total of 50 participants were recruited, with 25 women in each group. All subjects underwent serum AMH testing, and diagnoses were confirmed via histopathological examination. P